The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Flagged first, then by citations
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 701–800 of 1,002
Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial
Liu, Y., Bainbridge, J. L., Sillau, S., Rajkovic, S. N., Adkins, M., Domen, C. H., Thompson, J. A., Seawalt, T., Klawitter, J., Sempio, C., et al. (2024) · Movement Disorders · doi:10.1002/mds.29768 · Cited by 23
Molecular Mechanisms of Cannabis Signaling in the Brain
Ronan, P. J., Wongngamnit, N., & Beresford, T. P. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.10.002 · Cited by 25
Ongoing strategies and updates on pain management in gynecologic oncology patients
Hacker, K., Reynolds, R. K., & Uppal, S. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.01.034 · Cited by 23
Endogenous cannabinoid modulation of restraint stress‐induced analgesia in thermal nociception
Atwal, N., Winters, B. L., & Vaughan, C. W. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14884 · Cited by 25
Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer
Luo, C.-K., Chou, P.-H., Ng, S.-K., Lin, W.-Y., & Wei, T.-T. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00346-0 · Cited by 23
Lavender, I., McCartney, D., Marshall, N. S., Suraev, A. S., Irwin, C. G., D'Rozario, A. L., Gordon, C. J., Saini, B., Grunstein, R. R., Yee, B. J., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071148 · Cited by 22
Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts
Mick, G., & Douek, P. (2024) · Pain and Therapy · doi:10.1007/s40122-024-00643-0 · Cited by 25
Simei, J. L. Q., Souza, J. D. R., Pedrazzi, J. F. C., Guimarães, F. S., Campos, A. C., Zuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17121644 · Cited by 27
Boggs, D. L., Peckham, A. M., Boggs, A. A., & Ranganathan, M. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.11.277 · Cited by 24
Begleiterhebung zur Anwendung von Cannabisarzneimitteln in Deutschland – Zwischenauswertung
Schmidt‐Wolf, G., & Cremer-Schaeffer, P. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02968-0 · Cited by 22
Singh, V., Zarrabi, A. J., Curseen, K. A., Sniecinski, R. M., Welsh, J. W., McKenzie-Brown, A. M., Baer, W. M., & Gillespie, T. W. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00184 · Cited by 22
Whitcomb, B. P., Lutman, C. V., Pearl, M. L., Medlin, E. E., Prendergast, E. N., Robison, K. M., & Burke, W. M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.013 · Cited by 22
Curtis, S. A., Brandow, A. M., DeVeaux, M., Zeltermam, D., Devine, L., & Roberts, J. D. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0036 · Cited by 23
Krill, C., Rochfort, S. J., & SPANGENBERG, G. C. (2020) · Metabolites · doi:10.3390/metabo10070276 · Cited by 21
Update on cannabis and cannabinoids for cancer pain
Chung, M. J., Kim, H. K., & Abdi, S. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000934 · Cited by 24
Busardò, F. P., Pérez-Acevedo, A. P., Pacifici, R., Mannocchi, G., Gottardi, M., Papaseit, E., Pérez‐Mañá, C., Martín, S., Poyatos, L., Pichini, S., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14010059 · Cited by 22
Neuroimaging the Neuropathogenesis of HIV
Boerwinkle, A. H., Meeker, K. L., Luckett, P. H., & Ances, B. M. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00548-z · Cited by 22
Medicinal cannabis in children and adolescents with autism spectrum disorder: A scoping review
Fletcher, S., Pawliuk, C., Ip, A., Huh, L. L., Rassekh, S. R., Oberlander, T. F., & Siden, H. B. (2021) · Child Care Health and Development · doi:10.1111/cch.12909 · Cited by 24
Erukainure, O. L., Matsabisa, M. G., Salau, V. F., Oyedemi, S. O., Oyenihi, O. R., Ibeji, C. U., & Islam, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.705402 · Cited by 22
Ohtsuki, T., Friesen, J. B., Chen, S., McAlpine, J. B., & Pauli, G. F. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.1c00976 · Cited by 22
Online survey of medicinal cannabis users: Qualitative analysis of patient-level data
Garcia‐Romeu, A., Elmore, J. S., Mayhugh, R. E., Schlienz, N. J., Martin, E. L., Strickland, J. C., Bonn‐Miller, M. O., Jackson, H., & Vandrey, R. G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.965535 · Cited by 28
Sea, Y. L., Gee, Y. J., Lal, S. K., & Choo, W. S. (2022) · Journal of Applied Microbiology · doi:10.1093/jambio/lxac036 · Cited by 22
Paulke, A., Proschak, E., Sommer, K., Achenbach, J., Wunder, C., & Toennes, S. W. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.01.001 · Cited by 22
Cannabis-related cognitive impairment
Bar‐Sela, G., Tauber, D., Mitnik, I., Sheinman‐Yuffe, H., Bishara-Frolova, T., & Aharon‐Peretz, J. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000685 · Cited by 23
Halladay, J. E., Munn, C., Boyle, M., Jack, S. M., & Georgiades, K. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719854071 · Cited by 22
Pichini, S., Mannocchi, G., Berretta, P., Zaami, S., Pirani, F., Pacifici, R., & Busardò, F. P. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000683 · Cited by 22
Wendelboe, A. M., Mathew, R., Chongsuwat, T., Rainwater, E., Wendelboe, M. A., Wickersham, E., & Chou, A. F. (2019) · Journal of patient-centered research and reviews · doi:10.17294/2330-0698.1704 · Cited by 24
Potency Assessment of CBD Oils by Their Effects on Cell Signaling Pathways
Urasaki, Y., Beaumont, C., Workman, M., Talbot, J. N., Hill, D. K., & Le, T. T. (2020) · Nutrients · doi:10.3390/nu12020357 · Cited by 22
Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis
Becker, W., Alrafas, H. R., Busbee, P. B., Walla, M. D., Wilson, K. M., Miranda, K., Cai, G., Putluri, V., Putluri, N., Nagarkatti, M., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa253 · Cited by 23
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
Fitzcharles, M., & Häuser, W. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0625-5 · Cited by 24
Sarkis, S., Chamard, C., Johansen, B., Daïen, V., & Michon, F. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1527319 · Cited by 27
Janero, D. R., & Thakur, G. A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1245289 · Cited by 21
Cannabinoids for the treatment of dementia
Marković, D., Bošnjak, D., Brković, T., Jerić, M., Rubić, Ž., Vuica, A., & Puljak, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012820 · Cited by 21
The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis
Kopelli, E., Samara, M. T., Siargkas, A., Goulas, A., Papazisis, G., & Chourdakis, M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113246 · Cited by 21
Novel Analgesics with Peripheral Targets
Ciotu, C. I., & Fischer, M. J. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00937-z · Cited by 22
Cardiovascular Effects of Medical Marijuana: A Systematic Review
Pasha, A. K., Clements, C. Y., Reynolds, C. A., Lopez, M. K., Lugo, C. A., Gonzalez, Y., Shirazi, F. “., & Abidov, A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.015 · Cited by 21
Clinician Beliefs and Practices Related to Cannabis
Schauer, G. L., Njai, R. S., & Grant, A. M. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0165 · Cited by 21
Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors
Thippaiah, S. M., Iyengar, S. S., & Vinod, K. Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.636228 · Cited by 21
Pisani, S., McGoohan, K., Velayudhan, L., & Bhattacharyya, S. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00882-2 · Cited by 22
Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials
Traccis, F., Presciuttini, R., Pani, P. P., Sinclair, J., Leggio, L., & Agabio, R. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.019 · Cited by 23
Medical Cannabis: Toward a New Policy and Health Model for an Ancient Medicine
Fortin, D., Marcellin, F., Carrieri, P., Mancini, J., & Barré, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.904291 · Cited by 21
Eichler, F., Poźniak, B., Machnik, M., Schenk, I., Wingender, A., Baudisch, N., Thevis, M., Bäumer, W., Lischer, C. J., & Ehrle, A. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1234551 · Cited by 21
The endocannabinoid system, a novel and key participant in acupuncture’s multiple beneficial effects
Hu, B., Bai, F., Xiong, L., & Wang, Q. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.006 · Cited by 22
Analgesic Potential of Extracts and Derived Natural Products from Medicinal Plants
Rauf, A., Jehan, N., Ahmad, Z., & Mubarak, M. S. (2017) · InTech eBooks · doi:10.5772/intechopen.68631 · Cited by 21
Chronic pain and cannabinoids. Great expectations or a christmas carol
Pascual, D., Sánchez-Robles, E., García, M. M., & Goicoechea, C. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.033 · Cited by 22
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
Gado, F., Digiacomo, M., Macchia, M., Bertini, S., & Manera, C. (2018) · Medicines · doi:10.3390/medicines5030091 · Cited by 21
Cooper, Z. D., & Abrams, D. I. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1669628 · Cited by 21
Vulfsons, S., Minerbi, A., & Sahar, T. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10385 · Cited by 21
How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?
Vaseghi, S., Nasehi, M., & Zarrindast, M. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.018 · Cited by 21
Cannabis-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability
Baratta, F., Simiele, M., Pignata, I., Enri, L. R., D’Avolio, A., Torta, R., Luca, A. D., Collino, M., & Brusa, P. (2021) · Pharmaceuticals · doi:10.3390/ph14020171 · Cited by 21
Epidemiology of cannabidiol related cases reported in the National Poison Data System – 2019-2020
Berger, B. A., Stolz, U., Colvin, J. M., & Otten, E. J. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.04.065 · Cited by 21
González, J. M. P., & Silván, C. V. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1935879 · Cited by 23
Mechanisms and pharmacotherapy of cancer cachexia‐associated anorexia
Sato, R., da Fonseca, G. W. P., das Neves, W., & von Haehling, S. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70031 · Cited by 23
Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population
Highet, B. H., Lesser, E. R., Johnson, P. W., & Kaur, J. S. (2020) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909119900378 · Cited by 20
Johal, H. S., Vannabouathong, C., Chang, Y., Zhu, M. T., & Bhandari, M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20937968 · Cited by 20
Wallace, J. E., Kogan, L. R., Carr, E., & Hellyer, P. W. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-020-00045-x · Cited by 29
Deidda, R., Schelling, C., Roussel, J., Dispas, A., Bleye, C. D., Ziémons, E., Hubert, P., & Veuthey, J. (2020) · Analytical Science Advances · doi:10.1002/ansa.202000091 · Cited by 20
Use of psychotropic substances among elite athletes – a narrative review
Exner, J., Bitar, R., Berg, X., Pichler, E. M., Herdener, M., Seifritz, E., & Claussen, M. C. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20412 · Cited by 25
GPCR_LigandClassify.py; a rigorous machine learning classifier for GPCR targeting compounds
Ahmed, M., Hasani, H. J., Kalyaanamoorthy, S., & Barakat, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-88939-5 · Cited by 22
Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders
Ahmed, I., Rehman, S. U., Shahmohamadnejad, S., Zia, M. A., Ahmad, M. M., Saeed, M. M., Akram, Z., Iqbal, H. M. N., & Liu, Q. (2021) · Molecules · doi:10.3390/molecules26113389 · Cited by 20
Clinician Attitudes, Training, and Beliefs About Cannabis: An Interprofessional Assessment
Worster, B. K., Ashare, R. L., Hajjar, E. R., Garber, G. D., Smith, K. R., & Kelly, E. L. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0022 · Cited by 20
Cannabis Use Following Total Joint Arthroplasty is Associated With Increased Risks? A Meta-Analysis
Turan, O., Rullán, P. J., Pasqualini, I., Pumo, T. J., Surace, P. A., Murray, T. G., & Piuzzi, N. S. (2023) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.07.008 · Cited by 20
Medical Cannabis: A Review from the American Society of Pain and Neuroscience
Strand, N. H., D'Souza, R. S., Karri, J. V., Kalia, H., Weisbein, J. S., Kassa, B. J., Hussain, N., Chitneni, A., Budwany, R. R., Hagedorn, J. M., et al. (2023) · Journal of Pain Research · doi:10.2147/jpr.s425862 · Cited by 24
Emerging Treatments for Neuropathic Pain
Pessôa, B. L., Escudeiro, G. P., & Nascimento, O. J. M. (2015) · Current Pain and Headache Reports · doi:10.1007/s11916-015-0530-z · Cited by 20
Medicinal cannabis in Australia: the missing links
Martin, J. H., & Bonomo, Y. A. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00234 · Cited by 20
Mapping regulatory models for medicinal cannabis: a matrix of options
Běláčková, V., Shanahan, M., & Ritter, A. J. (2017) · Australian Health Review · doi:10.1071/ah16257 · Cited by 20
Investigating owner use of dietary supplements in dogs with idiopathic epilepsy
Berk, B., Packer, R. M. A., Law, T. H., & Volk, H. A. (2018) · Research in Veterinary Science · doi:10.1016/j.rvsc.2018.07.004 · Cited by 20
Palace, Z. J., & Reingold, D. A. (2018) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.11.013 · Cited by 20
Matched pilot study examining cannabis-based dronabinol for acute pain following traumatic injury
Schneider-Smith, E., Salottolo, K., Swartwood, C. J., Melvin, C., Madayag, R. M., & Bar‐Or, D. (2020) · Trauma Surgery & Acute Care Open · doi:10.1136/tsaco-2019-000391 · Cited by 22
Cannabis, e-cigarettes and anesthesia
Lynn, R. R., & Galinkin, J. L. (2020) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000872 · Cited by 23
Nasser, Y., Woo, M. M. K., & Andrews, C. N. (2020) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-020-00323-w · Cited by 20
Ramlagan, S., Peltzer, K., & Pengpid, S. (2021) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-021-00364-z · Cited by 20
Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations
Chang, Y., Zhu, M., Vannabouathong, C., Mundi, R., Chou, R. S., & Bhandari, M. (2021) · Pain Research and Management · doi:10.1155/2021/8857948 · Cited by 20
Bagüés, A., López‐Tofiño, Y., Llorente‐Berzal, A., & Abalo, R. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000667 · Cited by 18
Neuropathic pain treatment: still a challenge
Nascimento, O. J. M., Pessôa, B. L., Orsini, M. A., Ribeiro, P. F. M., Davidovich, E., Pupe, C., Filho, P. M., Dornas, R. M., Masiero, L., Bittencourt, J., et al. (2016) · Neurology International · doi:10.4081/ni.2016.6322 · Cited by 21
Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006–2015
Maloney-Hall, B., Wallingford, S. C., Konefal, S., & Young, M. M. (2020) · Health Promotion and Chronic Disease Prevention in Canada · doi:10.24095/hpcdp.40.5/6.06 · Cited by 21
An overview of phytochemical constituents and pharmacological implications of Cannabis sativa L.
Yadav, S. P. S., Kafle, M., Ghimire, N. P., Shah, N. K., Dahal, P., & Pokhrel, S. (2023) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2023.100798 · Cited by 22
A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
Cury, R. D. M., da Silva, T., Cezar‐dos‐Santos, F., Fakih, Y. R. C., Narvaez, K. A. R., Gouvea, M. C., Espínola, C., Ferreira, C. F., de Castro, W. A. C., Pamplona, F. A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251389608 · Cited by 22
Role of marijuana components on the regenerative ability of stem cells
Miller, H. P., Leo, N. D., Badach, J. M., Lin, A. B., Williamson, J., Bonawitz, S. C., & Ostrovsky, O. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3609 · Cited by 19
Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions
Vázquez, M., García‐Carnelli, C., Maldonado, C., & Fagiolino, P. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-61663-2_3 · Cited by 24
Phytocannabinoids Biosynthesis in Angiosperms, Fungi, and Liverworts and Their Versatile Role
Arif, Y., Singh, P., Bajguz, A., & Hayat, S. (2021) · Plants · doi:10.3390/plants10071307 · Cited by 19
Micro- and nanocarriers for pain alleviation
da Silva, A., Lepêtre‐Mouelhi, S., & Couvreur, P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114359 · Cited by 20
Clarke, S. J., Butcher, B., McLachlan, A. J., Henson, J. D., Rutolo, D., Hall, S., & Vitetta, L. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270543 · Cited by 22
Heavy Lifetime Cannabis Use and Mortality by Sex
Vallée, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.15227 · Cited by 19
Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids
Kuramoto, K., Wang, N., Fan, Y., Zhang, W., Schoenen, F. J., Frankowski, K. J., Marugán, J., Zhou, Y., Huang, S., & He, C. (2016) · Autophagy · doi:10.1080/15548627.2016.1187367 · Cited by 19
What do Providers Want to Know about Opioid Prescribing? A Qualitative Analysis of Their Questions
Cushman, P. A., Liebschutz, J. M., Hodgkin, J. G., Shanahan, C. W., White, J. L., Hardesty, I., & Alford, D. P. (2017) · Substance Abuse · doi:10.1080/08897077.2017.1296525 · Cited by 19
Collins, A. T., Ross, J., & Lang, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178645 · Cited by 18
Self-citationMedical Marijuana for Chronic Pain
Caulley, L., Caplan, B., & Ross, E. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmclde1808149 · Cited by 19
Baratta, F., Simiele, M., Pignata, I., Enri, L. R., Torta, R., Luca, A. D., Collino, M., D’Avolio, A., & Brusa, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00701 · Cited by 19
The Impact of Medical Marijuana Laws and Dispensaries on Self-Reported Health
Andreyeva, E., & Ukert, B. D. (2019) · Forum for Health Economics & Policy · doi:10.1515/fhep-2019-0002 · Cited by 19
Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio, N., Pietrafusa, N., & Cross, J. H. (2020) · Epileptic Disorders · doi:10.1684/epd.2019.1121 · Cited by 20
Management of Cannabinoid Hyperemesis Syndrome: Focus on Capsaicin
Stumpf, J. L., & Williams, L. D. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020934289 · Cited by 19
Khalid, S., Almalki, F. A., Hadda, T. B., Bader, A., Abu‐Izneid, T., Berredjem, M., Elsharkawy, E. R., & Alqahtani, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201202125807 · Cited by 20
Medical Cannabis in Oncology: a Valuable Unappreciated Remedy or an Undesirable Risk?
Abu-Amna, M., Salti, T., Khoury, M., Cohen, I., & Bar‐Sela, G. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00811-2 · Cited by 20
Riera, R., Pacheco, R. L., Bagattini, Â. M., & Martimbianco, A. L. C. (2021) · Phytotherapy Research · doi:10.1002/ptr.7263 · Cited by 19
Kendzor, D. E., Ehlke, S. J., Boozary, L. K., Smith, M., & Cohn, A. M. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101777 · Cited by 19
Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients
Deckey, D. G., Doan, M. K., Hassebrock, J. D., Patel, K. A., Economopoulos, K. J., Tokish, J. M., Bingham, J. S., & Chhabra, A. (2022) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671221087629 · Cited by 19
Cannabinoids for chronic neuropathic pain
Mücke, M., Phillips, T., Radbruch, L., Petzke, F. W., & Häuser, W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012182 · Cited by 18
Hutchison, K. E., Hagerty, S. L., Galinkin, J., Bryan, A. D., & Bidwell, L. C. (2019) · Cannabis & Cannabinoid Research · doi:10.1089/can.2018.0052 · Cited by 18
Monton, C., Madaka, F., Settharaksa, S., Wunnakup, T., Suksaeree, J., & Songsak, T. (2019) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201920190676 · Cited by 20
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
